Naltrexone transmucosal - Bionex Pharmaceuticals

Drug Profile

Naltrexone transmucosal - Bionex Pharmaceuticals

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator Bionex Pharmaceuticals
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Irritable bowel syndrome therapies; Morphinans; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Alcoholism

Most Recent Events

  • 16 Nov 2016 Chemical structure information added
  • 14 Nov 2016 Early research development is ongoing for Alcoholism in USA (Bionex Pharmaceuticals website, November 2016)
  • 30 Sep 2012 Bionex Pharmaceuticals receives phase II SBIR grant from National Institute on Alcohol Abuse and Alcoholism for naltrexone transmucosal development in Alcoholism (3207875; Bionex Pharmaceutical website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top